Company News: Page (1) of 1 - 02/13/18 Email this story to a friend. email article Print this page (Article printing at page facebook

Nivolumab immunotherapy safe and feasible during chemoradiation for advanced head and neck cancer

RTOG Foundation 3504 safety evaluation trial finds immune checkpoint blocker did not compromise ability to complete first-line therapy and was tolerated well for a year following treatment (February 13, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Presentors,Business Issues,Presentation,People,Training,Events,email, Inc.,Disease,Cancer,Surgery,Science,Lifestyle,Medical,Biology,Physics,Cancer,Science,Email,Other,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved